Where are the new drugs to treat heart failure? Introduction to the special issue on "Key signaling molecules in hypertrophy and heart failure"

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 435-437

  Simpson, Paul C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ALPHA ADRENERGIC RECEPTOR; BETA ARRESTIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CARDIAC MYOSIN; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; HEAT SHOCK PROTEIN 20; HISTONE DEACETYLASE; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NEU DIFFERENTIATION FACTOR; NEUROTROPHIC FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE C ALPHA; PROTEIN KINASE PIM 1; SIRTUIN 1; TETRAHYDROBIOPTERIN; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

EDITORIAL; FUNDING; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART PROTECTION; HUMAN; MEDICAL SOCIETY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH;

ANIMALS; CARDIOMEGALY; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HEART FAILURE; HUMANS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80052787391     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.08.005     Document Type: Editorial

References (42)

1. Massie B.M. Novel targets for the treatment of heart failure: perspectives from a heart failure clinician and trialist. J Mol Cell Cardiol. 2011, 51(4):438-440.
2. Lathrop D.A., Skarlatos S. Current NHLBI perspectives on translational heart failure research. J Mol Cell Cardiol. 2011, 51(4):441-443.
3. Plump A., Madwed J. Heart failure drug discovery: scarred or ready for remodeling?. J Mol Cell Cardiol. 2011, 51(4):444-448.
4. van der Worp H.B., Macleod M.R. Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol. 2011, 51(4):449-450.
5. Mochly-Rosen D., Grimes K.V. Myocardial salvage in acute myocardial infarction-challenge in clinical translation. J Mol Cell Cardiol. 2011, 51(4):451-453.
6. Malik F.I., Morgan B.P. Cardiac myosin activation part 1: From concept to clinic. J Mol Cell Cardiol. 2011, 51(4):454-461.
7. Kanashiro-Takeuchi R.M., Schulman I.H., Hare J.M. Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol. 2011, 51(4):619-625.
8. Arsanjani R., McCarren M., Bahl J.J., Goldman S. Translational potential of thyroid hormone and its analogs. J Mol Cell Cardiol. 2011, 51(4):506-511.
9. Sawyer D.B., Caggiano A. Neuregulin-1beta for the treatment of systolic heart failure. J Mol Cell Cardiol. 2011, 51(4):501-505.
10. Marber M.S., Rose B., Wang Y. The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol. 2011, 51(4):485-490.
11. Liu Q., Molkentin J.D. Protein kinase Calpha as a heart failure therapeutic target. J Mol Cell Cardiol. 2011, 51(4):474-478.
12. Jensen B.C., O'Connell T.D., Simpson P.C. Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 2011, 51(4):518-528.
13. Bolli R., Becker L., Gross G., Mentzer R., Balshaw D., Lathrop D.A. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004 Jul 23, 95(2):125-134.
14. Begley S., Carmichael M. Desperately seeking cures: medical research isn't making progress rapidly enough; here's why-and how to push things forward. Newsweek. 2010; May 24 & 31(): 38-42. http://www.thedailybeast.com/newsweek/2010/05/15/desperately-seeking-cures.html.
15. Wood S.G. Pfizer to drop development of drugs for hyperlipidemia, atherosclerosis, and heart failure 2008, http://wwwtheheartorg/article/908435do.
16. Bolli R. Announcing increased word limits and two new additions to our article portfolio. Perspectives and Translational Success Stories. Circ Res 2011, 109:350.
17. Collins F.S. Reengineering translational science: the time is right. Sci Transl Med Jul 6 2011, 3(90). 90cm17.
18. Felker G.M., Pang P.S., Adams K.F., Cleland J.G., Cotter G., Dickstein K., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010 Mar, 3(2):314-325.
19. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V., et al. Can animal models of disease reliably inform human studies?. PLoS Med 2010, 7(3):e1000245.
20. Jessup M., Greenberg B., Mancini D., Cappola T., Pauly D.F., Jaski B., et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation Jul 19 2011, 124(3):304-313.
21. Neill U.S. You know what we need?. J Clin Invest Aug 1 2011, 121(8):2948.
22. Dobaczewski M., Chen W., Frangogiannis N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol. 2011, 51(4):600-606.
23. Glembotski C.C. Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure. J Mol Cell Cardiol. 2011, 51(4):512-517.
24. Talan M.I., Ahmet I., Xiao R.P., Lakatta E.G. beta(2) AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol. 2011, 51(4):529-533.
25. Noor N., Patel C.B., Rockman H.A. beta-Arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol. 2011, 51(4):534-541.
26. Anderson M.E., Brown J.H., Bers D.M. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011, 51(4):468-473.
27. Iwata M., Cowling R.T., Yeo S.J., Greenberg B. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol. 2011, 51(4):542-547.
28. Cheng H., Woodgett J., Maamari M., Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol. 2011, 51(4):607-613.
29. Kim M., Tian R. Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol. 2011, 51(4):548-553.
30. Sundaresan N.R., Pillai V.B., Gupta M.P. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol. 2011, 51(4):614-618.
31. Ferreira J.C., Brum P.C., Mochly-Rosen D. betaIIPKC and epsilonPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol. 2011, 51(4):479-484.
32. Moens A.L., Kietadisorn R., Lin J.Y., Kass D. Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. J Mol Cell Cardiol. 2011, 51(4):559-563.
33. Moens A.L., Ketner E.A., Takimoto E., Schmidt T.S., O'Neill C.A., Wolin M.S., et al. Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. J Mol Cell Cardiol. 2011, 51(4):564-569.
34. Fischer K.M., Cottage C.T., Konstandin M.H., Volkers M., Khan M., Sussman M.A. Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling. J Mol Cell Cardiol. 2011, 51(4):554-558.
35. McKinsey T.A. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol. 2011, 51(4):491-496.
36. Kamal F.A., Smrcka A.V., Blaxall B.C. Taking the heart failure battle inside the cell: small molecule targeting of Gbetagamma subunits. J Mol Cell Cardiol. 2011, 51(4):462-467.
37. Matsushima S., Zablocki D., Sadoshima J. Application of recombinant thioredoxin1 for treatment of heart disease. J Mol Cell Cardiol. 2011, 51(4):570-573.
38. Nemchenko A., Chiong M., Turer A., Lavandero S., Hill J.A. Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol. 2011, 51(4):584-593.
39. Dorn G.W. Nix nought nothing: fairy tale or real deal. J Mol Cell Cardiol. 2011, 51(4):497-500.
40. Fan G.C., Kranias E.G. Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failure. J Mol Cell Cardiol. 2011, 51(4):574-577.
41. Topkara V.K., Evans S., Zhang W., Epelman S., Staloch L., Barger P.M., et al. Therapeutic targeting of innate immunity in the failing heart. J Mol Cell Cardiol. 2011, 51(4):594-599.
42. Schilling J., Kelly D.P. The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 2011, 51(4):578-583.